跳至主要内容
临床试验/NCT03993093
NCT03993093已完成不适用

AIDS Defining Opportunistic Infections in Naive HIV Cases

Singh, Ranjan Kumar, M.D.1 个研究点 分布在 1 个国家目标入组 257 人开始时间: 2019年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
257
试验地点
1
主要终点
Prevalence of AIDS defining OIs

研究概览

简要总结

HIV patients are likely to suffer from opportunistic infections, in absence of highly active retroviral therapy. This happens due to lack of awareness of HIV status among patients or unresponsive to anti retroviral drugs. This study is for the prevalence of AIDS defining OIs among treatment naive HIV patients.

详细描述

Oppotunistic infections (OIs) happen in persons with weakened immune system. HIV patients, who remain untreated due to lack of knowledge of existing HIV infections, often get OIs. HIV patients with AIDS defining OIs fall into stage 3 of HIV illness. Prevalence of OIs in resource poor settings are tuberculosis (pulmonary and extra pulmonary), toxoplasmosis, cryptococcosis, and oesophageal candidiasis. There are a few data to show AIDS defining OIs in treatment naïve HIV patients. Incidence of OIs among HIV patients in United States, and Canada between 2000 to 2019 was 9%. Leading OIs were peumocystis Jiroveci, oesophageal candidiasis and disseminated MAC or M. kansassi.

Minimal diagnoses at poor settings can be made by observation of symptoms, use of microscope, imaging and diagnostic therapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
5 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HAART naïve HIV patient

排除标准

  • Patients died during screening
  • Transferred in HIV patients

结局指标

主要结局

Prevalence of AIDS defining OIs

时间窗: Six months

Calculate number of total HIV patients with or without opportunistic infections (n). Again calculate no of HIV patients with opportunistic infections (n1). Then calculate prevalence of HIV +ve patients with opportunistic infections by applying formula n1/n x100.

次要结局

  • Compare CD4 cell in cases of HIV with OIs with CD4 cell of HIV patients without OIs(Six months)

研究者

发起方
Singh, Ranjan Kumar, M.D.
申办方类型
Indiv
责任方
Principal Investigator
主要研究者

Ranjan Kumar Singh

Physician, cum nodal officer, ART centre Khagaria

Singh, Ranjan Kumar, M.D.

研究点 (1)

Loading locations...

相似试验